Apollo is reportedly exploring a purchase of DePuy Synthes, Johnson & Johnson's orthopaedics business, in a transaction that could value the unit at roughly $20 billion. The business generated $9.3 billion of revenue in 2025, while a public-company separation remains another possible route.

Neither company has confirmed a final transaction. Johnson & Johnson had previously announced plans to separate the business over 18 to 24 months as it concentrates on faster-growing health segments. Hospitals should therefore plan around scenarios, not assume a buyer or timetable.

What ownership could change

Private ownership can accelerate cost discipline, portfolio simplification, distribution changes and investment in digital services around surgery. It can also create pressure to improve margins quickly. For customers, the practical questions concern supply continuity, training, maintenance, product road maps and contract terms.

Gulf hospitals should map their dependence on individual implant systems and instrument sets. Clinical protocols, surgeon training and inventory can make switching more difficult than changing an ordinary supplier. Contingency planning needs clinically acceptable alternatives, not only procurement backups.

Source: Reuters — 11 September 2026 and Johnson & Johnson.

Karim's strategic takeaway

Ownership headlines matter when they alter service reliability at the operating-room level. Hospitals should use the uncertainty to review concentration risk before any transaction changes commercial terms.